Immusoft inks deal with Takeda on rare neurometabolic disorders
Seattle, USA-based cell therapy company Immusoft has signed a research collaboration and license option agreement with Japan’s Takeda Pharmaceutical (TYO: 4502) to discover, develop and commercialize transformative cell therapies in rare inherited metabolic disorders with central nervous system (CNS) manifestations and complications using Immusoft’s Immune System Programming (ISP) technology platform, which modifies a patient’s B cells and instructs the cells to deliver gene-encoded therapies.
The collaboration will focus on delivering protein therapeutics across the blood-brain barrier, a promising area of Immusoft’s research, which has the potential to enable the treatment of diseases with high unmet need.
The core components of Immusoft’s Immune System Programming (ISP) technology were developed in the Baltimore Lab at the California Institute of Technology (Caltech) and exclusively licensed by Immusoft.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze